Immunity against heterosubtypic influenza virus induced by adenovirus and mva expressing nucleoprotein and matrix protein-1

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Lambe, Teresa ^a   Carey, John B ^b   Li, Yuanyuan ^a   Spencer, Alexandra J ^a   Van Laarhoven, Arjan ^a   Mullarkey, Caitlin E ^a   Vrdoljak, Anto ^b   Moore, Anne C ^b   Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; CYTOKINE; GAMMA INTERFERON; INFLUENZA VACCINE; M1 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; NP PROTEIN, INFLUENZA A VIRUS; RNA BINDING PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CD8+ T LYMPHOCYTE; CYTOLOGY; FEMALE; GENE VECTOR; GENETICS; IMMUNIZATION; IMMUNOLOGY; INFLUENZA VIRUS A; INTRADERMAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MOUSE; ORTHOMYXOVIRUS INFECTION; SPLEEN; VACCINIA VIRUS;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; GENETIC VECTORS; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; INFLUENZAVIRUS A; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; RNA-BINDING PROTEINS; SPLEEN; VACCINIA VIRUS; VIRAL CORE PROTEINS; VIRAL MATRIX PROTEINS;

EID: 84875150077     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01443     Document Type: Article

References (37)

1. Cowling, B. J. et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clinical infectious diseases 51, 1370-1379 (2010).
2. Mathews, J. D.,McBryde, E. S., McVernon, J., Pallaghy, P. K.&McCaw, J.M. Prior immunity helps to explain wave-like behaviour of pandemic influenza in 1918-9. BMC infectious diseases 10, 128 (2010).
3. Lambe, T. Novel viral vectored vaccines for the prevention of influenza. MolMed 18, 1153-1160 (2012).
4. Gilbert, S. C. Advances in the development of universal influenza vaccines. Influenza Other Respi Viruses (2012).
5. Arinaminpathy, N. et al. Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza. Proceedings of the National Academy of Sciences of the United States of America 109, 3173-3177 (2012).
6. Lee, L. Y. et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118, 3478-3490 (2008).
7. Epstein, S. L. et al. Protection against multiple influenza Asubtypes by vaccination with highly conserved nucleoprotein. Vaccine (2005).
8. Berthoud, T. K. et al. Potent CD81 T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP1M1. Clinical Infectious Diseases 52, 1-7 (2011).
9. Price, G. E. et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 5, e13162 (2010).
10. Roy, C. J. et al. Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method. Respir Res 12, 153 (2011).
11. Belshe, R. B. et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356, 685-696 (2007).
12. Patel, V. et al. Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 28, 4827-4836 (2010).
13. Kaufman, D. R., Bivas-Benita, M., Simmons, N. L., Miller, D. & Barouch, D. H. Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD81 T lymphocytes. J Virol 84, 5986-5996 (2010).
14. Holland, D. et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 198, 650-658 (2008).
15. Draper, S. J. et al. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 185, 7583-7595 (2010).
16. Sheehy, S. H. et al. Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 andMVA Vaccine Vectors. PLoS One 7, e31208 (2012).
17. Bodmer, H. C., Pemberton, R. M., Rothbard, J. B. & Askonas, B. A. Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein. Cell 52, 253-258 (1988). (Pubitemid 18042859)
18. Epstein, S. L. & Price, G. E. Cross-protective immunity to influenza A viruses. Expert review of vaccines 9, 1325-1341 (2010).
19. Stanekova, Z. & Vareckova, E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 7, 351 (2010).
20. Schotsaert, M., Saelens, X.&Leroux-Roels, G. Influenza vaccines: T-cell responses deserve more attention. Expert Rev Vaccines 11, 949-962 (2012).
21. Hillaire, M. L., Osterhaus, A. D. & Rimmelzwaan, G. F. Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. Journal of biomedicine & biotechnology 2011, 939860 (2011).
22. Lambe, T. et al. T-Cell Responses in Children to Internal Influenza Antigens, 1 Year after Immunization with Pandemic H1N1 Influenza Vaccine, and Response to Revaccination with Seasonal Trivalent Inactivated Influenza Vaccine. The Pediatric Infectious Disease Journal (2012).
23. Bodewes, R. et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One 4, e5538 (2009).
24. Bodewes, R. et al. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol 85, 2695-2702 (2011).
25. Skowronski, D. M. et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS medicine 7, e1000258 (2010).
26. Janjua, N. Z. et al. Seasonal influenza vaccine and increased risk of pandemic A/H1N1-related illness: first detection of the association in British Columbia, Canada. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 51, 1017-1027 (2010).
27. Berthoud, T. K. et al. Potent CD81 T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP1M1. Clin Infect Dis 52, 1-7 (2011).
28. Lillie, P. J. et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP1M1, in humans. Clin Infect Dis 55, 19-25 (2012).
29. Dicks, M. D. et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7, e40385 (2012).
30. Schneider, J. et al. Enhanced immunogenicity for CD81 T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4, 397-402 (1998). (Pubitemid 28212753)
31. Dunachie, S. J. et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 74, 5933-5942 (2006). (Pubitemid 44484581)
32. McShane, H. et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10, 1240-1244 (2004). (Pubitemid 39540442)
33. Pavot, V., Rochereau, N., Genin, C., Verrier, B. & Paul, S. New insights in mucosal vaccine development. Vaccine 30, 142-154 (2012).
34. Takamura, S. et al. The route of priming influences the ability of respiratory virusspecific memory CD81 T cells to be activated by residual antigen. J Exp Med 207, 1153-1160 (2010).
35. Shen, X.,Wong, S. B., Buck, C. B., Zhang, J. & Siliciano, R. F. Direct priming and cross-priming contribute differentially to the induction of CD81 CTL following exposure to vaccinia virus via different routes. J Immunol 169, 4222-4229 (2002). (Pubitemid 35178193)
36. Belkaid, Y. & Oldenhove, G. Tuning microenvironments: induction of regulatory T cells by dendritic cells. Immunity 29, 362-371 (2008).
37. Townsend, A. R. & Skehel, J. J. The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells. J Exp Med 160, 552-563 (1984). (Pubitemid 14052516)